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Abstract : The most common site of distant metastasis from colorectal cancer is 
the liver, and hepatectomy presents the best curative treatment for recurrence 
of colorectal liver metastasis （CRLM）.  This study aimed to identify factors of 
prognostic value for repeat hepatectomy for CRLM and to determine whether a 
third such procedure could similarly produce favourable outcomes for CRLM.  We 
analyzed data for 161 patients in our department with colorectal metastasis.  Of 
these, 22 patients underwent repeat hepatectomy for recurrent metastasis, with 16 
undergoing a second hepatectomy and 6 a third hepatectomy.  We analyzed patient 
characteristics, tumor status, operation-related variables, and short- and long-term 
outcomes.  Univariate analysis for repeat hepatectomy identied the following ve 
prognostic risk factors: T factor （＞SE） of the primary cancer, number of tumors 
involved in the initial hepatectomy （＞5）, interval from rst to second hepatectomy 
（＜ 1 year）, number of tumors involved in second hepatectomy （＞3）, and post-
operation time （＞30 days）.  By multivariate analysis, T factor （＞SE） of the 
primary cancer, number of tumors in the initial hepatectomy （＞5）, and number 
of tumors in the second hepatectomy （＞3） were independently associated with a 
worse survival after surgery for CRLM.  Although surgical outcomes of the third 
hepatectomy were not compared with those of the rst and second hepatectomy, 
there were no obvious differences, nor did the 1-, 3-, and 5-year survival rates dif-
fer signicantly among the three groups.  Repeat hepatectomy for CRLM could 
improve long-term  survival.  In addition, patients undergoing a third hepatectomy 
showed a similar survival benet to those having one or two resections.
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Introduction
　The liver is the most common organ for metastasis from colorectal cancer, and despite 
colorectal liver metastasis （CRLM） being classified as distant, hepatectomy offers the best 
chance of cure with 5-year survival rates of 30–50％ 1，2）.  Unfortunately, 45–80％ of patients who 
undergo hepatectomy for CRLM develop recurrence3–6）, although 30％ of patients have recurrent 
spots only in the liver after hepatic resection 5） and are potentially candidates for further 
resection 7-9）.  In addition, recent innovations in combination chemotherapy, such as FOLFOX 
or FORFIRI with targeted therapies, have also extended remarkable surgical opportunities to 
patients with unresectable metastasis 10-12）.  Such advances in surgical techniques and perioperative 
management have enabled some centers to perform repeat hepatectomy in selected groups of 
patients 13–16）, with 5-year survival rates currently at 21–41％ for repeat hepatectomy17-19）.  Thus, 
repeat hepatic resections for CRLM are increasingly performed under appropriate conditions in 
selected patients.  
　Previous studies have evaluated factors associated with favorable outcome after a repeat 
hepatectomy, without clarity.  In addition, a third hepatectomy for CRLM is considered more 
complex and associated with a higher incidence of complications 20–22）, although few reports have 
documented the surgical outcomes based on individual factors23–25）.   
　This study thus aimed to identify factors associated with repeat hepatectomy that are of 
prognostic value for CRLM and to determine whether a third hepatectomy could be performed 
with similarly acceptable surgical outcomes.   
Patients and methods 
　From January 1998 to October 2015, 161 patients underwent a liver resection for CRLM in 
our surgical department.  These patients were divided into three groups: first resection only （n＝
139）, second resection （n＝16）, and third resection （n＝6）.  No patient underwent more than 
three resections.  We identified patients from prospective databases, and retrospectively reviewed 
office and hospital charts.  The median follow-up time from primary colon surgery was 52.3 
months.
　The selection criteria for hepatectomy were the presence of technically resectable liver 
metastasis, the possibility of an oncological radical operation, and the absence of any unresectable 
extra-hepatic disease.  Extra-hepatic disease was defined as infiltration of contiguous structures, 
presence of other distant metastasis, or local recurrence of the primary colorectal tumor.  The 
indication for repeat hepatectomy was not limited by number of metastatic tumors, tumor 
size, or disease-free interval from initial hepatectomy.  Following the primary colorectal tumor 
resection or after each hepatectomy, we performed a careful search for local recurrence, 
extrahepatic metastasis, and peritoneal dissemination.  The patients were followed up every 3 
months for the first postoperative year, then every 6 months during the subsequent 2 years, and 
then at 12-month intervals to postoperative year 5; the follow-up comprised liver function tests, 
serum carcinoembryonic antigen （CEA） testing, thoracic and abdominal computed tomography 
357The Surgical Benefits of Repeat Hepatectomy for CRLM
（CT）, and colonoscopy （CS）.  
　Morbidity was defined by complications during hospitalization or within 30 days following 
the resection, based on abdominal wall morbidity （wound infections and wound dehiscence）, 
intraperitoneal morbidity （bleeding, abscess, peritonitis, and biliary fistula, etc）, and medical 
complications （septicemia from extra-abdominal causes; catheter, respiratory, and urinary 
infections; and, other systemic non-infectious complications）.  Mortality was defined as deaths 
occurring during hospitalization or within 30 days.
　Statistical analysis was conducted using JMP software （version 13, Inc., SAS Institute）.  All 
means are expressed with standard deviation （SD）.  Survival probabilities were estimated using 
the Kaplan-Meier method, while univariate associations between potential risk factors and 
survival were assessed using the log-rank test with two-tailed hypothesis.  Factors identified in 
univariate associations were assessed using the Cox multivariate regression test.  The significance 
level of P＜0.05 was used in all hypothesis testing.
　The Showa University School of Medicine Ethics Committee approved the experimental 
protocols used in this study （#2924）.
Results 
1. Factors of prognostic value for repeat hepatectomy 
　We analyzed the data for 16 of the 161 study patients to investigate the prognostic value 
of repeat hepatectomy for CRLM （Table 1）.  The mean age of this subgroup was 65.6 years 
（range: 35–85） and the mean 5-year survival rate for repeat hepatectomy was 66.1％.  The 
primary tumor was carcinoma of the colon in 8 patients and carcinoma of the rectum in 8 
patients, while liver metastasis was synchronous in 9 patients （56.2％）.  The mean interval 
between colectomy and the first hepatectomy was 5.7 months, with 87.5％ of the patients 
undergoing the hepatectomy within 1 year.  In terms of patient characteristics, neither age nor 
gender predicted the long-term outcome, but primary tumor status and T factor （＞SE） of the 
primary tumor were predictive factors （P＝ 0.028）.  Invaded depth, lymph node status, and 
CEA level （＞ 5 ng/ml） were also not predictive of the outcome.  In terms of the initial liver 
metastatic status, number of tumors in the initial hepatectomy （＞ 5） predicted the outcome 
（P＝ 0.021）, whereas tumor size （＞ 50 mm） and CEA level （＞ 5 ng/ml） were not predictive of 
the outcome.  The interval from first to second hepatectomy （＜ 1 year） predicted the outcome 
（P＝ 0.031）, as did tumor number in the second hepatectomy （＞ 3） （P＝ 0.047）.  Size of 
tumor （＞ 50 mm） and CEA level （＞ 5 ng/ml） were again not associated with outcome.  In 
terms of operation-related variables, only postoperative hospital stay （＞ 30 days） was predictive 
of the outcome （P＝ 0.019）, with blood loss （＞ 2,000 ml）, operation time （＞ 500 min）, and 
morbidity showing no predictive value （Table 2）.  Our multivariate analysis identified T factor 
（＞ SE） of the primary tumor （P＝ 0.024, risk ratio 1.93, 95％CI 1.50-1.61）, tumor number at 
initial hepatectomy （＞ 5） （P＝ 0.024, risk ratio 2.35, 95％CI 1.13-1.65） and tumor number at 
second hepatectomy （＞ 3） （P＝ 0.045, risk ratio 2.83, 95％CI 1.07-1.10） were independently 
associated with a worse survival after surgery for CRLM （Table 3）.  
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2. Operative outcomes for third hepatectomy
  The patients in this study were divided according to their number of resections, i.e., 
3 resections （n＝6）, 2 resections （n＝16）, or a single resection （n＝139）.  The disease 
characteristics at hepatectomy for all patients are summarized in Table 4.  The patient 
characteristics, tumor status, operation-related variables, and short- and long-term outcomes 
were analyzed including age, gender, pathology and depth of the primary tumor, lymph node 
metastasis from the primary tumor, lymphatic or vascular invasion of the primary tumor, CEA 
level of primary tumor and CRLM, blood platelet count （PLT）, liver Child-Pugh classification, 
indocyanine green retention 15 （ICG R15）, 99mTc-galactosyl serum albumin （99mTc-GSA）, tumor 
number, and maximum tumor diameter.  
　The only significant difference among the three groups was in the H classification of the 
primary tumor （P＝ 0.01）.  All cases of third hepatectomy were synchronous, and although 
there was significantly less operation-associated blood loss with the third hepatectomy compared 
to that for the first and second hepatectomy （P＝ 0.03）, operation time and blood loss 
were not significantly different across the groups.  There was no intraoperative mortality. 
Complications included liver-related complications （perihepatic abscess: n＝ 9, bile fistula: n＝
Table 1.　Characteristics of repeat hepatectomy for CRLM
Characteristics n＝ 16
Age
Gender （M/F）
Location of primary tumor
　colon （A/T/D/S）
　rectum
Interval time from primary operation
　metachronous
　synchronous
First hepatectomy
　number of tumor
　tumor size （mm）
　operative methods （Hr 0/Hr S/Hr ＞1）
　operative time （min）
　blood loss （ml）
　operative morbidity （＞grade 3） （％）
　post-operative chemotherapy （Y/N）
Interval time from first hepatectomy （days）
Second hepatectomy
　number of tumor
　tumor size （mm）
　operative methods （Hr 0/Hr S/Hr ＞1）
　operative time （min）
　blood loss （ml）
　operative morbidity （＞grade 3） （％）
　operative mortality （％）
　post-operative chemotherapy （Y/N）
Time until recurrence （days）
5-year survival rate after second hepatectomy （％）
65.6 （35-85）
12/4
8 （2/0/2/4）
8
9
7 （43.8％）
 2.47 （1-6）
32.8  （4-85）
8/3/4
293 （125-615）
365   （5-1,240）
8 （50.0％）/8 （50.0％）
8.3
412 （46-1,060）
 1.9  （1-7）
31.9 （12-50）
12/3/1
265 （95-710）
742  （5-3,435）
0 
0
6 （37.5％）/10 （62.5％）
446 （75-1,574）
66.1
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Table 2.　Univariate predictors repeat hepatectomy for CRLM
Number of patients  5-year survival rate （％） P value
Age
　＜70 years
　＞70 years
Gender
　male
　female
Primary tumor
　CEA level
　　＜ 5 ng/ml
　　＞ 5 ng/ml
　T factor
　　＜SE
　　＞SE
　N factor
　　＜N1
　　＞N1
Interval time from primary operation
　metachronous
　synchronous
First hepatectomy
　number of tumor
　　＞5
　　＜5
　size of tumor
　　＜50 mm
　　＞50 mm
　CEA level
　　＜ 5 ng/ml
　　＞ 5 ng/ml
post-operative chemotherapy
　Yes
　N o
Interval time from rst hepatectomy
　＞1year
　＜1year
Second hepatectomy
　number of tumor
　　＞ 3
　　＜ 3
　size of tumor
　　＞50 mm
　　＜50 mm
　CEA level
　　＜ 5 ng/ml
　　＞ 5 ng/ml
　operative time
　　＜500 min
　　＞500 min
　blood loss
　　＜2,000 ml
　　＞2,000 ml
　post-operative hospital stay
　　＜30 days
　　＞30 days
　post-operative chemotherapy
　　Yes
　　N o
9
7
12
4
3
8
11
2
6
7
9
6
13
2
11
4
4
11
8
7
9
7
13
3
12
2
5
9
12
2
12
2
12
2
6
9
50
57
64
0
50
54
63
0
53
46
63
33
65
0
54
67
100
43
55
42
32
75
61
33
48
50
67
35
49
50
49
50
56
0
33
68
0.50
0.156
0.493
0.028
0.340
0.695
0.021
0.754
0.220
0.651
0.031
0.047
0.485
0.319
0.980
0.980
0.019
0.228
Tomokazu KUSANO, et al360
5, and post-operative liver failure: n＝ 1） and general complications （surgical site infection: n
＝ 5, pneumonitis: n＝ 2, and other: n＝ 3）.  Ten cases showed complications of grade-Ⅲa and 
over （Clavien-Dindo classification）, namely perihepatic abscess （n＝ 5） and bile fistula （n＝ 4） 
at first hepatectomy, and bile fistula （n＝ 1） at third hepatectomy.  Post-operative hospital stay 
also did not differ among the three groups, nor did the 1-, 3-, and 5-year survival rates （100.0, 
83.3, and 62.5％ for the third hepatectomy group vs. 100.0, 79.3, and 66.1％ for the second 
hepatectomy group vs.  87.5, 59.8, and 47.6％ for the first hepatectomy group） （Fig. 1）.  
Discussion
　For recurrence cases of CRLM, 20–41％ of recurrence was localized at the liver and thus 
potentially amenable to further hepatic resection 17-19）.  In addition, repeat hepatic resection for 
CRLM is an increasingly effective treatment when performed under appropriate conditions 20, 26-29）.  
　This study aimed to detect criteria of prognostic value for repeat hepatectomy for CRLM. 
We identified five such factors by single-variable analysis, namely T factor of primary tumor （＞
SE）, tumor number at initial hepatectomy （＞ 5）, interval from first to second hepatectomy 
（＜ 1 year）, tumor number at second hepatectomy （＞ 3）, and postoperative day （＞ 30 days）. 
Subsequent multivariate analysis identified T factor （＞SE） of the primary cancer, tumor number 
at initial hepatectomy （＞ 5） and tumor number at second hepatectomy （＞ 3） as predictive 
of the outcome.  A previous review reported six predictors for length of survival after repeat 
hepatectomy 30）, being disease-free survival after first hepatectomy of ＞ 1 year, solitary CRLM, 
unilobar CRLM, maximal size of CRLM ＜ 5 cm, lack of extrahepatic metastases, and R0 
resection at repeat hepatectomy.  Number of liver metastasis for CRLM and interval from first 
to second hepatectomy （＜ 1 year） were also important prognostic factors in our study and in 
previous work.  Although all studies including this one analyzed tumor location as a factor, 
no reports cited extrahepatic metastases and R0 resection as important.  We also found no 
prognostic value associated with maximum tumor size of CRLM or postoperative chemotherapy.
　Another aim of this study was to investigate the surgical benefits of a third hepatectomy for 
CRLM.  Comparing the surgical outcomes of patients undergoing three hepatectomies with those 
undergoing one or two hepatectomies found no worsening of the following factors after the 
third operation: preoperative liver function, PLT, Child-Pugh classification, ICG R15, and 99mTc-
Table 3.　Multivariate predictors of repeat hepatectomy for CRLM
Factor P-value HR（95％CI）
T factor of primary tumor　＞SE 0.024 1.93（1.50-1.61）
Number of nodules for rst hepatectomy ＞5 0.024 2.35（1.13-1.65）
Interval time from rst hepatectomy ＜1 year 0.395 0.29（0.01-7.33）
Number of nodules for Repeat hepatectomy ＞3 0.045 2.83（1.07-1.10）
Post-operative hospital stay ＞30 days 0.621 0.45（0.01-13.90）
Values in parentheses are 95％ condence intervals.
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Table 4.　Characteristics of third hepatectomy for CRLM
Characteristics Third hepatectomy First hepatectomy Second hepatectomy
（n＝ 6） （n＝ 139） P value＊ （n＝ 16） P value＊＊
Age 68.7（58-78） 67.9（37-89） 0.85 65.6 （35-85） 0.63
Gender（M/F） 4/2 72/51 0.90 12/4 0.70
Primary tumor factor
　Location
　 （C/A/T/D/S/R） 0/0/1/1/2/2 6/21/4/8/25/51 - 0/2/0/2/3/8 -
　CEA level （ng/ml） 56.2（3.1-141） 60.8（1.4-567） 0.91 36.4（1.6-176） 0.53
　Pathology
　 （tub1/ tub2/other） 0/6/0 33/60/10 0.13 5/8/0 0.08
　Depth
　 （MP/SS/＞SE） 0/5/1 6/68/34 0.62 3/8/2 0.43
　Lymph node
　 （N0/N1/N2/N3） 2/4/0/0 37/40/19/9 0.58 6/3/3/1 0.42
　Lymphatic invasion
　 （ly0/ly1/ly2/ly3） 2/4/0/0 19/53/24/5 0.50 1/6/3/2 0.24
　Vascular invasion
　 （v0/v1/v2/v3） 2/1/2/1 14/44/29/13 0.47 1/2/7/2 0.57
　H classification
　 （H0/H1/H2/H3） 0/5/1/0 51/21/12/7 0.01 7/5/1/0 0.08
　Onset of liver metastasis
　 （Synchro/Metachro） 0/6 51/40 0.01 7/6 0.08
　M classification
　 （M0/M1） 5/1 88/6 0.34 12/0 0.15
Liver metastasis factor
　Liver function
　　PLT （104/µl） 25.5 （22.5-29.4） 24.4（8.5-47.6） 0.78 22.4 （13.4-40.8） 0.48
　Child-Pugh classification 5.0 （5-5） 5.11 （5-7） 0.49 5.14 （5-6） 0.40
　ICG 15 （％） 9.8 （5-19） 10.1 （3-29） 0.90 18.6 （9-43） 0.17
　LHL15 （GSA） 0.91 （0.85-0.94） 0.84 （0.63-0.96） 0.57 0.89 （0.82-0.96） 0.92
　Location
　 （S1/2/3/4/
　　    5/6/7/8）
0/0/1/0/
     0/3/1/1
6/13/10/14
        24/24/19/14 -
0/1/1/1/
     5/3/3/1 -
　CEA level （ng/ml） 31.8 （5.5-99.7） 80.5（1.2-2313） 0.65 18.8 （1.4-56.5） 0.46
　Number of tumor 1.7 （1-3） 2.4 （1-13） 0.44 1.9 （1-7） 0.71
　Maximum Diameter （mm） 37.0 （15-50） 34.8 （1.0-160） 0.86 31.9 （12-50） 0.42
Operative factor
　Methods
　 （Hr0/HrS/Hr1/＞Hr2） 3/2/1/0 89/19/14/13 - 12/3/1/0 -
　 （Hr0/＞HrS） 3/3 89/46 0.41 12/4 0.26
　Time （min） 461 （275-470） 323 （47-815） 0.07 265 （95-710） 0.03
　Blood loss （ml） 788 （425-997） 580 （5-3475） 0.07 742 （5-3435） 0.28
　Morbidity （＞Clavien Ⅲa） 1 9 0.01 0 0.20
　Hospital stay （days） 16.5 （11-27） 22.2 （4-136） 0.57 17.5 （5-49） 0.87
＊: Third hepatectomy vs First hepatectomy　＊＊: Third hepatectomy vs Second hepatectomy
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GSA.  As severe adhesions are generally caused by repetitive tissue separations, we suspect 
that operative time and blood loss in the third hepatectomy cases were inferior to those during 
the first or second surgeries, although in our cases, only operative blood loss with the third 
hepatectomy vs second hepatectomy was inferior.  Of note, almost all of the third hepatectomy 
cases analyzed herein were performed at the time prior to anti-adhesive material being used.  In 
addition, the main operative technique of this study was laparoscopy and partial hepatectomy, 
providing a minimally invasive surgery compared to the open method, while partial hepatectomy 
involves only a small resection of parenchymal transection.  Thus, it is not surprising that 
there were few complication risks with the analyzed patients.  Cases receiving neoadjuvant 
chemotherapy were also scarce in this study, thus we could not include that factor in the 
analysis.  Regardless, the present study revealed that a third hepatectomy was safe to perform 
and provided survival benefits and rates comparable to those of previous liver resections without 
increasing mortality or morbidity.  
Conclusion
　Repeat hepatectomy for CRLM can achieve long-term  survival by selective classification of 
patients, with the number of liver metastases a particularly important factor of prognostic value. 
Additionally, a third hepatectomy had a similar survival benefit as first or second resections, and 
long-term survival was achieved in selected patients following careful classification.   
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